These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1715080)

  • 1. Investigation on serum neurone-specific enolase in prostate cancer diagnosis and monitoring: comparative study of a multiple tumor marker assay.
    Tarle M; Radoś N
    Prostate; 1991; 19(1):23-33. PubMed ID: 1715080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NK cell activity in treated prostate cancer patients as a probe for circulating tumor cells: hormone regulatory effects in vivo.
    Kastelan M; Kraljić I; Tarle M
    Prostate; 1992; 21(2):111-20. PubMed ID: 1384013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
    Tarle M
    Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A more objective staging of advanced prostate cancer--routine recognition of malignant endocrine structures: the assessment of serum TPS, PSA, and NSE values.
    Tarle M; Frković-Grazio S; Kraljić I; Kovacić K
    Prostate; 1994; 24(3):143-8. PubMed ID: 7509485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor markers in patients with chronic renal failure.
    Filella X; Cases A; Molina R; Jo J; Bedini JL; Revert L; Ballesta AM
    Int J Biol Markers; 1990; 5(2):85-8. PubMed ID: 1704405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings?
    Angelsen A; Syversen U; Haugen OA; Stridsberg M; Mjølnerød OK; Waldum HL
    Prostate; 1997 Jan; 30(1):1-6. PubMed ID: 9018329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum chromogranin-A in advanced prostate cancer.
    Ferrero-Poüs M; Hersant AM; Pecking A; Brésard-Leroy M; Pichon MF
    BJU Int; 2001 Nov; 88(7):790-6. PubMed ID: 11890255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy.
    Kamiya N; Akakura K; Suzuki H; Isshiki S; Komiya A; Ueda T; Ito H
    Eur Urol; 2003 Sep; 44(3):309-14; discussion 314. PubMed ID: 12932928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer.
    Lilleby W; Paus E; Skovlund E; Fosså SD
    Prostate; 2001 Feb; 46(2):126-33. PubMed ID: 11170140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer.
    Fan L; Wang Y; Chi C; Pan J; Xun S; Xin Z; Hu J; Zhou L; Dong B; Xue W
    BJU Int; 2017 Aug; 120(2):226-232. PubMed ID: 28107595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
    Tarle M; Kovacić K; Kastelan M
    Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.
    Seidman AD; Scher HI; Petrylak D; Dershaw DD; Curley T
    J Urol; 1992 Mar; 147(3 Pt 2):931-4. PubMed ID: 1371564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients.
    Zhang L; Liu D; Li L; Pu D; Zhou P; Jing Y; Yu H; Wang Y; Zhu Y; He Y; Li Y; Zhao S; Qiu Z; Li W
    BMC Cancer; 2017 Feb; 17(1):96. PubMed ID: 28152979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma.
    Fizazi K; Cojean I; Pignon JP; Rixe O; Gatineau M; Hadef S; Arriagada R; Baldeyrou P; Comoy E; Le Chevalier T
    Cancer; 1998 Mar; 82(6):1049-55. PubMed ID: 9506348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Markers of undiagnosed incidental cancer in comparison with clinical prostatic cancer.
    Ogawa A; Yoshida A; Kanda T; Sugihara S; Suzuki T; Tamura J; Kobayashi I; Nakazato Y
    J Med; 2000; 31(1-2):101-10. PubMed ID: 10998759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of lung cancer based on serum biomarkers by gene expression programming methods.
    Yu Z; Chen XZ; Cui LH; Si HZ; Lu HJ; Liu SH
    Asian Pac J Cancer Prev; 2014; 15(21):9367-73. PubMed ID: 25422226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
    Jiang ZF; Wang M; Xu JL
    Life Sci; 2018 Feb; 194():1-6. PubMed ID: 29247745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of haptoglobin in combination with CEA, NSE and CYFRA21-1 for diagnosis of lung cancer.
    Wang B; He YJ; Tian YX; Yang RN; Zhu YR; Qiu H
    Asian Pac J Cancer Prev; 2014; 15(22):9611-4. PubMed ID: 25520076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
    Ebert W; Hoppe M; Muley T; Drings P
    Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical usefulness of serum assays of neuron-specific enolase, carcinoembryonic antigen and CA-50 antigen in the diagnosis of lung cancer.
    Bergman B; Brezicka FT; Engström CP; Larsson S
    Eur J Cancer; 1993; 29A(2):198-202. PubMed ID: 8380696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.